All donations up to $200,000 matched before June 30 Donate
The Cancer Research Institute funds the full spectrum of discovery,
from lab to clinic to cure—making maximum impact on the future of cancer treatment.
Working in tandem with our growing network of researchers, supporters, patients, and ImmunoAdvocates, we're funding the best scientists doing the best research—all while promoting awareness, sharing up-to-date Immunotherapy information, and inspiring lifelong advocacy for the cause.
We support the science behind the treatment, funding lifesaving immunotherapy research and clinical trials around the world.
Apply for Grants & Fellowships
Meet Our Scientists
Your trusted resource for the latest credible, accurate cancer immunotherapy information for scientists, patients, and supporters.
Learn How Immunotherapy Works
See How Immunotherapy Impacts All Cancers
Join us in the cause to cure all cancers, advancing immunotherapy through events and awareness campaigns.
Create a Fundraising Team
Attend a CRI Event
Connecting you to an inspiring network of patients and advocates—that's a crucial part of our mission. See real stories of immunotherapy experiences, or share your own with others looking for insight and information.
Meet Your ImmunoCommunity
Find a Clinical Trial
We are the Cancer Research Institute, a powerful organization of research scientists and leadership staff dedicated to an important mission. Together, we work to develop immunotherapy as a cure for all cancers, connect a community of Immunoadvocates, and pave the way for a future free from cancer.
We're working for you—all of our supporters, patients, and scientists—to make the biggest impact possible in our efforts to cure cancer.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Cancer Research Institute held its annual Through the Kitchen benefit party yesterday evening and raised $1.4 million to fund six promising postdoctoral fellows over three years.
A second CAR T cell immunotherapy targeting the CD19 receptor was approved by the FDA for patients with relapsed or refractory large B cell lymphoma.